CD markers (short for “cluster of differentiation”) are proteins on the surface of blood cells that tell a laboratory what kind of cell it is looking at. In leukemia, the pattern of CD markers on the cancer cells identifies whether the disease is myeloid or lymphoid, B-cell or T-cell, acute or chronic. That pattern, called the immunophenotype, shapes the diagnosis, the treatment choice, and how response is tracked afterwards.
If your report lists a string of numbers like “CD19+, CD10+, CD34+”, this guide explains what those results mean and why they matter.
What CD Markers Are
Every blood cell carries a set of surface proteins that reflects its lineage and stage of maturity. Scientists gave these proteins standardized “CD” numbers so that laboratories worldwide use the same names. More than 300 have been catalogued, but a few dozen do most of the work in diagnosing hematologic cancers.
Normal cells gain and lose markers in an orderly way as they mature. Leukemia cells are stuck at an early stage or show unusual combinations, and that abnormal profile is what makes them identifiable. For a wider look at the disease, see our leukemia guide.
How CD markers are measured
The main tool is flow cytometry. Cells from blood or bone marrow are tagged with antibodies carrying fluorescent labels, then passed one by one through a laser. The machine records which markers each cell carries, and can analyze many thousands of cells in minutes. Immunohistochemistry, which stains markers on a bone marrow biopsy slide, is a complementary method.
Key CD Markers and What They Indicate
No single marker diagnoses leukemia. Hematologists read the whole panel, looking at which markers are present, which are absent, and how strongly each is expressed.
| Marker | Usually found on | Why it matters in leukemia |
|---|---|---|
| CD34 | Stem cells and early blasts | Marks immature cells in many acute leukemias |
| CD117 | Early myeloid cells | Supports a myeloid (AML) lineage |
| CD13, CD33 | Myeloid cells | Core myeloid markers; CD33 is a drug target |
| CD14, CD64 | Monocytes | Point to monocytic types of AML |
| CD19, CD22, CD79a | B cells | Define B-cell lineage; CD19 and CD22 are drug targets |
| CD10 | Early B cells | Common in B-cell acute lymphoblastic leukemia |
| CD20 | Mature B cells | Target for rituximab and similar antibodies |
| CD3, CD7 | T cells | Cytoplasmic CD3 defines T-cell lineage |
| CD5, CD23 | Some B cells | Together with CD19, typical of CLL |
| CD123 | Plasmacytoid dendritic cells, some blasts | Diagnostic and therapeutic target in rare leukemias |
How CD Markers Classify Leukemia
The diagnosis of leukemia combines the blood count, the appearance of cells under the microscope, CD marker results, and genetic testing. Immunophenotyping answers the lineage question quickly, often within a day.
Acute myeloid leukemia (AML)
AML blasts usually express myeloid markers such as CD13, CD33, and CD117, often with CD34. Acute promyelocytic leukemia, an emergency subtype, typically lacks CD34 and HLA-DR, a pattern that can prompt urgent treatment while genetic confirmation is pending.
Acute lymphoblastic leukemia (ALL)
B-cell ALL shows CD19, CD79a, and CD22, frequently with CD10 and CD34. T-cell ALL is identified by cytoplasmic CD3 together with markers like CD7. The enzyme TdT, although not a CD marker, is usually tested alongside to confirm the cells are immature lymphoblasts.
Chronic lymphocytic leukemia (CLL)
CLL has a characteristic signature: B-cell markers CD19 and CD5 together with CD23, with weak CD20. A related lymphoma, mantle cell lymphoma, also carries CD5 but usually lacks CD23, so this one marker helps separate two diseases with very different treatment.
Mixed-phenotype acute leukemia
Occasionally the blasts carry strong markers of two lineages. This is recognized as a distinct, less common category, and flow cytometry is the only way to identify it.
From Sample to Report: The Testing Process
CD marker testing is one part of a broader workup, described in our overview of testing for leukemia in adults. A typical sequence looks like this:
- Complete blood count and smear show abnormal cells or blasts.
- Flow cytometry on peripheral blood or bone marrow establishes the immunophenotype.
- Bone marrow aspirate and biopsy measure the blast percentage and marrow cellularity.
- Cytogenetics and molecular tests, such as karyotype, FISH, PCR, and next-generation sequencing, identify genetic changes that refine prognosis.
Our guide to leukemia diagnosis tests explains each of these in more detail.
Measuring minimal residual disease
After treatment, the same marker profile becomes a fingerprint. Because leukemia cells carry an unusual combination of markers, sensitive flow cytometry can find a few remaining leukemia cells among many thousands of normal ones. This is called minimal (or measurable) residual disease (MRD), and it is one of the strongest predictors of relapse risk in ALL and increasingly in AML.
Targeted Treatments Built on CD Markers
CD markers do more than name the disease. Several of the most effective modern treatments are aimed directly at them, which is why leukemia treatment planning starts with the immunophenotype.
- CD20: monoclonal antibodies such as rituximab and obinutuzumab, widely used in CLL.
- CD19: blinatumomab, a bispecific T-cell engager that links leukemia cells to the patient’s T cells, and CD19-directed CAR T-cell therapy for B-cell ALL.
- CD22: inotuzumab ozogamicin, an antibody-drug conjugate for B-cell ALL.
- CD33: gemtuzumab ozogamicin, an antibody-drug conjugate used in selected AML.
- CD123: tagraxofusp, used in blastic plasmacytoid dendritic cell neoplasm, a rare disease closely related to leukemia.
Leukemia cells can lose a targeted marker under treatment pressure, a problem called antigen escape. Relapse without CD19 after CD19-directed therapy is the best-known example, and it is why marker testing is repeated at relapse.
Research Directions
Research is focused on markers that are present on leukemia cells but spare healthy stem cells, which is the main challenge in AML because myeloid targets like CD33 and CD123 also appear on normal marrow cells. Work is also under way on CAR T-cell products that recognize two markers at once to reduce antigen escape, and on standardizing MRD methods across laboratories. Outcomes with these approaches continue to be studied, and data on leukemia survival are regularly updated as they enter routine care.
Key Takeaways
- CD markers are surface proteins that reveal the lineage and maturity of leukemia cells.
- Flow cytometry reads a panel of markers to separate AML, B-ALL, T-ALL, CLL, and rarer types.
- The same marker profile is used to detect minimal residual disease after treatment.
- Antibodies, antibody-drug conjugates, bispecific engagers, and CAR T cells are aimed at specific CD markers.
Frequently Asked Questions
What does “CD19 positive” mean on my report?
It means the abnormal cells carry the CD19 protein, which marks them as B-lineage cells. This is typical of B-cell ALL and CLL. It also means CD19-directed treatments may be an option at some point.
Can CD markers alone diagnose leukemia?
No. They are combined with the blood count, the microscope findings, the blast percentage in the marrow, and genetic tests. A marker pattern can strongly suggest a diagnosis, but the full picture confirms it.
Why was flow cytometry repeated after my treatment?
Repeat testing looks for minimal residual disease, meaning leukemia cells too few to see under a microscope. The result helps your team judge how deep the response is and whether more treatment is needed.
Can the CD markers on leukemia cells change?
Yes. Leukemia can change its profile over time, especially after targeted therapy. That is why markers are rechecked at relapse before choosing the next treatment.
